BPC-157 vs GHK-Cu for pain & inflammation
Short answer: For pain & inflammation, users rate them about the same: 86% report improvement with BPC-157 (485 reports) and 90% with GHK-Cu (31 reports).
BPC-157 has 0 meta-analyses and 0 randomized trials on PubMed; GHK-Cu has 0 and 1.
Based on 1,613 reports about BPC-157 and 496 about GHK-Cu. Not medical advice.
| BPC-157 Peptide | GHK-Cu Peptide | |
|---|---|---|
| Users say it helped | 54%helped919 reports · high confidence | 62%helped223 reports · high confidence |
| Verdict | Mixed | Mostly positive |
| Research | DResearch: None | CResearch: Limited |
| Meta-analyses / RCTs | 0 / 0 | 0 / 1 |
| Mainly used for | ||
| Recovery % reporting improvement | 96% (494) | 96% (27) |
| Pain & inflammation % reporting improvement | 86% (485) | 90% (31) |
| Skin & hair % reporting improvement | 90% (29) | 87% (202) |
| Mood % reporting improvement | 65% (128) | 86% (7) |
| Digestion % reporting improvement | 84% (111) | 100% (4) |
| Common side effects | fatigue, anhedonia, anxiety, headache | injection site, redness, stinging, injection pain |
| Typical dose reported | Not listed | Not listed |
BPC-157Full BPC-157 profile →
What a user said
“after 2+ years of nothing working, this is the 1st thing to reverse significant muscle damage ... 40% increase in my range of motion, and nearly the same in muscle strength.”
GHK-CuFull GHK-Cu profile →
What a user said
“Love it. 44 F. Totally helped even out my skin tone (Irish red cheeks), reduced wrinkles on my forehead and neck, thickened my hair which had been thinning, and grew my eye lashes.”
Related comparisons
Percentages come from first-hand user reports and are not clinical outcomes. Talk to a doctor before starting, stopping or combining anything. How we rate